Zinzani, P. L. Et Al. 2023. waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16 .

Zinzani, P. L., Mayer, J., Benjamini, O., Berkovits, A., Glimelius, I., Stevens, D. A., ... Chaudhry, A.(2023). waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

Zinzani, Pier Et Al. "waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Zinzani, Pier L. Et Al. "waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16, 2023

Zinzani, P. L. Et Al. (2023) . "waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.16.

@article{article, author={Pier Luigi Zinzani Et Al. }, title={waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023}